A cosmetic clinic in Australia is typically worth 2–4x adjusted EBITDA, or roughly 40–60% of annual gross revenue — and the two methods usually land within 10% of each other if your margins are healthy. The spread between a 2x deal and a 4x deal is almost entirely explained by one question: how much of the revenue depends on you personally? A clinic where two employed nurse practitioners do 90% of the treatments is a very different business from a solo owner-operator who does everything themselves and happens to have nice decor.
If you’re close to retirement, thinking about a partial exit, or just want to know what you’ve actually built, here’s how the numbers work — and why cosmetic clinics can be surprisingly tricky to value.
What Cosmetic Clinics Actually Sell For
In Australia, cosmetic clinics built around injectables, laser, IPL, skin treatments and body contouring generally trade on EBITDA multiples of 2–4x for owner-operated single-site businesses and up to 5–6x for multi-site or highly systematised practices that are already operating at arm’s length from the founder. To put a rough number on it: a single-location clinic generating $350,000 in adjusted EBITDA per year might sell for somewhere between $700,000 and $1.4 million, depending on how well it’s set up for a buyer.
The revenue-based approach acts as a cross-check. A clinic turning over $1.2 million with normal aesthetics margins should sit somewhere between $480,000 and $720,000 on a 40–60% revenue multiple. If the EBITDA multiple and the revenue multiple produce very different numbers, something is worth investigating — either the margins are unusual for the category, or the add-backs being claimed are aggressive.
The cosmetic injectables industry was valued at $4.1 billion in Australia in 2024. Despite that scale, most individual clinic sales in the $1M–$8M revenue range happen quietly — no listing, no public process. You’re selling into a small pool of qualified acquirers: private equity-backed aesthetic groups, direct competitors looking for geographic expansion, and the occasional ambitious associate who wants to buy you out. Understanding who those buyers are shapes how you position the business.
It’s worth noting that cosmetic clinics command higher multiples than traditional beauty salons — which typically sell for 1–2x EBITDA — because of their stronger margins, higher average transaction values, and the clinical expertise barrier to entry. The regulatory complexity cuts both ways: it’s a moat, but it’s also a complication at sale.
The Three Things That Drive Your Multiple Up or Down
Owner-dependency is the single biggest factor. If you’re the only AHPRA-registered practitioner, the only person who administers Schedule 4 substances, and the only face your patients book with — a buyer prices all of that risk in. Hard. (And they should, because when you leave, those patients have no particular reason to stay.) A practice where revenue is spread across two or three practitioners, and where patients book based on the clinic’s brand rather than you specifically, commands a meaningfully higher multiple.
Treatment mix matters more than most owners expect. Injectable-only businesses are fast, profitable and popular — but they’re also increasingly commoditised, dependent on product rep relationships, and exposed to TGA advertising restrictions. Clinics that have built out laser, skin, and body treatment revenue alongside injectables are more defensible; buyers see breadth and reduced category concentration risk.
The lease is the third leg. A cosmetic clinic with 30 months left on a poorly negotiated lease in a strip where the landlord has already signalled they want the space back is a very different risk profile from one with a 5+5 year option in a medical hub in the inner suburbs. If you’re thinking about selling in the next two years, now is the time to renegotiate, not when you’re sitting across the table from a buyer who’s just flagged the lease as a problem.
The AHPRA Problem — and How Buyers Price It In
This is the part that catches many cosmetic clinic owners off guard. AHPRA registration, prescriber authority, and poisons permits for Schedule 4 substances (like anti-wrinkle injectables) are personal to the individual practitioner. They don’t transfer with the business entity. When a clinic changes hands, the buyer needs their own registered practitioners in place from the moment settlement occurs.
For a buyer who is themselves a registered nurse, nurse practitioner or doctor, this is manageable — they step into the clinical role directly. For an investment group buying through a corporate entity, they need a compliant clinical governance structure already in place before settlement. Either way, the handover creates complexity, and that complexity gets reflected in the deal structure: longer transition periods, earn-outs, or a modest discount to the headline multiple.
TGA advertising compliance deserves equal attention. The restrictions on advertising Schedule 4 cosmetic treatments in Australia are significant, and they extend to social media. Anything that names a specific injectable product, uses before-and-after images for a proscribed treatment, or implies a particular clinical outcome from a scheduled substance is technically non-compliant. A buyer who finds a four-year archive of non-compliant Instagram posts during due diligence will want indemnification — which isn’t the conversation you want to be having at exchange. A compliance audit of your marketing materials before going to market is table stakes.
What Add-Backs Look Like in a Cosmetic Clinic
Most cosmetic clinic owner-operators run personal expenses through the business — and in aesthetics, those expenses can be substantial. Training trips, industry conferences, a vehicle, advanced courses in techniques the principal wants to develop. These are legitimate add-backs when calculating adjusted EBITDA for sale purposes.
What also gets reclassified is the owner’s remuneration. If you’re paying yourself $280,000 a year but a market-rate employed nurse practitioner would cost $140,000, the difference is part of the business’s true earning capacity. A buyer will model this regardless; better to present it clearly than let them discover it and wonder what else has been structured advantageously.
Product cost arrangements are worth scrutinising too. Some clinic owners have long-standing buy rates on injectables that sit well below what a new owner could negotiate. If those arrangements are personal to you and don’t survive the sale, the buyer’s operating economics look worse than your P&L suggests. Get clear on which purchasing advantages transfer and which don’t.
For a thorough treatment of how to present these adjustments, see our guide to EBITDA add-backs when selling a business.
What Buyers Check in Due Diligence
A serious buyer of a cosmetic clinic will work through the standard due diligence checklist — financials, lease, staff contracts, IP — but there are a few clinic-specific items that tend to receive particular scrutiny.
Patient database quality. Volume is less important than recency and retention. A buyer wants to see active patients who have returned within the past 18 months, not a database padded with people who had one appointment four years ago. Average transaction value and rebooking rate are the numbers that matter.
Regulatory file. Facility registration, practitioner rosters, consent protocols, poisons registers — a well-maintained regulatory file signals that compliance has been taken seriously. A disorganised one signals the opposite, and buyers discount accordingly.
Practitioner contracts. Staff with no written employment contract, no restraint-of-trade clause, or no non-solicitation provisions are a liability. If a key practitioner walks out six months after settlement and takes their patient list to a competitor two streets away, the buyer bears that loss. They’ll want to know that risk is contained before they sign.
Equipment ownership and condition. Laser and body treatment equipment is expensive and depreciates fast. A buyer doing their numbers will check whether equipment is owned outright or financed, what the maintenance records look like, and when key devices are due for servicing or replacement.
For more on managing key person risk when selling, particularly the practitioner dependency question, that’s worth reading before you go to market.
How to Increase Your Clinic’s Value Before You Sell
If you’re 18–24 months from wanting to exit, here’s where to focus.
Hire an associate and let them build a patient base of their own. Twelve months of an employed practitioner generating their own bookings shifts you from “entirely owner-dependent” to “partially systematised” — a real change in how a buyer models risk, and one that can move the multiple more than almost anything else.
Standardise everything that can be standardised. Treatment protocols, aftercare documentation, consent processes, pricing structures. Not because buyers want a folder of policies to read, but because documented systems are evidence that the business can run without you. The best version of this is a junior practitioner who can follow your protocols unsupervised.
Separate your personal profile from the clinic’s marketing. Your 40,000 Instagram followers followed you — they didn’t follow the clinic. An advisory firm I know worked on a transaction last year where the buyer walked away from an otherwise clean deal because the clinic’s social media presence was entirely personal: built on the vendor’s individual account, in her name, with no brand presence the business entity owned. The business had no transferable audience. That deal died at heads of agreement.
Renew the lease. If you have less than four years remaining, a buyer financing the purchase through a bank will struggle with lender approval. A clean 5+5 with CPI-linked rent reviews is worth the negotiation effort.
The valuation calculator will give you a working estimate based on your actual numbers. If you’re thinking about a sale in the next two years, the best time to talk to an adviser is now — the difference between preparing well and selling cold is usually measured in hundreds of thousands of dollars, and the aesthetics market is moving quickly enough that timing matters.